Laura Maggino

Laura Maggino

Auto-generated profile, based on publicly available information

Laura Maggino

Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, University of Verona Hospital Trust, Verona, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2015 in Gut
Verified
Journal Article
Closed access
PDF file
BJB Jais
B Jais
VRV Rebours
V Rebours
GMGiuseppe Malleo
Giuseppe Malleo
RSRoberto Salvia
Roberto Salvia
MFM Fontana
M Fontana
PLP Lévy
P Lévy
Objectives Serous cystic neoplasm (SCN) is a cystic neoplasm of the pancreas whose natural history is poorly known. The purpose of the study was to attempt to describe the natural history of SCN, including the specific mortality. Design Retrospective multinational study including SCN diagnosed between 1990 and 2014. Results 2622 patients were included. Seventy-four per cent were women, and median age at diagnosis was 58 years (16–99). Patients presented with non-specific abdominal pain (27%), pancreaticobiliary symptoms (9%), diabetes mellitus (5%), other symptoms (4%) and/or were asymptomatic (61%). Fifty-two per cent of patients were operated on during the first year after diagnosis (median size: 40 mm (2–200)), 9% had resection beyond 1 year of follow-up (3 years (1–20), size at diagnosis: 25 mm (4–140)) and 39% had no surgery (3.6 years (1–23), 25.5 mm (1–200)). Surgical indications were (not exclusive) uncertain diagnosis (60%), symptoms (23%), size increase (12%), large size (6%) and adjacent organ compression (5%). In patients followed beyond 1 year (n=1271), size increased in 37% (growth rate: 4 mm/year), was stable in 57% and decreased in 6%. Three serous cystadenocarcinomas were recorded. Postoperative mortality was 0.6% (n=10), and SCN's related mortality was 0.1% (n=1). Conclusions After a 3-year follow-up, clinical relevant symptoms occurred in a very small proportion of patients and size slowly increased in less than half. Surgical treatment should be proposed only for diagnosis remaining uncertain after complete workup, significant and related symptoms or exceptionally when exists concern with malignancy. This study supports an initial conservative management in the majority of patients with SCN. Trial registration number IRB 00006477.

1 December 2018 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
SRStijn van Roessel
Stijn van Roessel
GKGyulnara G. Kasumova
Gyulnara G. Kasumova
JVJoanne Verheij
Joanne Verheij
RNRobert M. Najarian
Robert M. Najarian
LMLaura Maggino
Laura Maggino
MBMarc G. Besselink
Marc G. Besselink
Over the past decades, the American Joint Committee on Cancer (AJCC) has established a well-defined system for cancer staging based on 3 key components: local tumor extent (T stage), dissemination to the regional lymph nodes (N stage), and metastatic spread to distant sites (M stage) (TNM staging).1 The AJCC TNM staging system attempts to use anatomical and reproducible parameters to discriminate groups with different survival outcomes.1-4 Reliable prediction of survival estimates is of paramount importance in cancer care. Accurate prognostication helps clinicians in guiding treatment decisions, provides researchers with a tool to adjust for cancer stage in evaluating treatment outcomes, and is informative to patients themselves.5,6

1 January 2019 in Annals of Surgery
Verified
Journal Article
Closed access
PDF file
BEBrett L. Ecker
Brett L. Ecker
MMMatthew T. McMillan
Matthew T. McMillan
VAValentina Allegrini
Valentina Allegrini
CBClaudio Bassi
Claudio Bassi
JBJoal D. Beane
Joal D. Beane
CVCharles M. Vollmer
Charles M. Vollmer
Objective: To identify a clinical fistula risk score following distal pancreatectomy. Background: Clinically relevant pancreatic fistula (CR-POPF) following distal pancreatectomy (DP) is a dominant contributor to procedural morbidity, yet risk factors attributable to CR-POPF and effective practices to reduce its occurrence remain elusive. Methods: This multinational, retrospective study of 2026 DPs involved 52 surgeons at 10 institutions (2001–2016). CR-POPFs were defined by 2016 International Study Group criteria, and risk models generated using stepwise logistic regression analysis were evaluated by c-statistic. Mitigation strategies were assessed by regression modeling while controlling for identified risk factors and treating institution. Results: CR-POPF occurred following 306 (15.1%) DPs. Risk factors independently associated with CR-POPF included: age (<60 yrs: OR 1.42, 95% CI 1.05–1.82), obesity (OR 1.54, 95% CI 1.19–2.12), hypoalbuminenia (OR 1.63, 95% CI 1.06–2.51), the absence of epidural anesthesia (OR 1.59, 95% CI 1.17–2.16), neuroendocrine or nonmalignant pathology (OR 1.56, 95% CI 1.18–2.06), concomitant splenectomy (OR 1.99, 95% CI 1.25–3.17), and vascular resection (OR 2.29, 95% CI 1.25–3.17). After adjusting for inherent risk between cases by multivariable regression, the following were not independently associated with CR-POPF: method of transection, suture ligation of the pancreatic duct, staple size, the use of staple line reinforcement, tissue patches, biologic sealants, or prophylactic octreotide. Intraoperative drainage was associated with a greater fistula rate (OR 2.09, 95% CI 1.51–3.78) but reduced fistula severity (P < 0.001). Conclusions: From this large analysis of pancreatic fistula following DP, CR-POPF occurrence cannot be reliably predicted. Opportunities for developing a risk score model are limited for performing risk-adjusted analyses of mitigation strategies and surgeon performance.

1 July 2016 in Surgery
Verified
Journal Article
Closed access
MTMichael Tachezy
Michael Tachezy
FGFlorian Gebauer
Florian Gebauer
MJMonika Janot
Monika Janot
WUWaldemar Uhl
Waldemar Uhl
AZAlessandro Zerbi
Alessandro Zerbi
MBMaximilian Bockhorn
Maximilian Bockhorn

1 October 2019 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
LMLaura Maggino
Laura Maggino
GMGiuseppe Malleo
Giuseppe Malleo
GMGiovanni Marchegiani
Giovanni Marchegiani
EVElena Viviani
Elena Viviani
CNChiara Nessi
Chiara Nessi
RSRoberto Salvia
Roberto Salvia
In the context of localized pancreatic ductal adenocarcinoma (PDAC), chemotherapy is the preferential induction strategy for locally advanced (LA) and borderline resectable (BR) disease.1-3 The recent steady uptake of primary chemotherapy has been fostered by newly introduced combinations, such as FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and gemcitabine plus nanoparticple albumin-bound (nab)–paclitaxel, which demonstrated a high response rate in randomized clinical trials of patients with metastatic disease.4,5 Although the translation of these regimens to earlier stages was empirical, several case series reported encouraging outcomes, with resection rates after primary chemotherapy ranging from 60% to 78%.6-11 However, these data are based on the patient pool selected for surgical exploration and not on the overall number of individuals with new diagnoses. At a collective level, a sizable amount of patients are indeed elderly or present with certain conditions (eg, jaundice, poor hematologic function of poor performance status) that hinder treatment eligibility and enrollment in controlled research protocols.12-14 Furthermore, a limitation of most studies is the inability to determine how many patients receiving primary chemotherapy never qualified for surgery because of treatment discontinuation, disease progression, or death.15-22

17 May 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
IFIsabella Frigerio
Isabella Frigerio
PRPaolo Regi
Paolo Regi
AGAlessandro Giardino
Alessandro Giardino
FSFilippo Scopelliti
Filippo Scopelliti
RGRoberto Girelli
Roberto Girelli
GBGiovanni Butturini
Giovanni Butturini